GleamWall
中文EN

FHTX Foghorn Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1822462 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY357.3%
TTM net income YoY113.1%
TTM EPS YoY107.9%
Revenue 3-yr CAGR51.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin2.1%
Net margin8.4%
FCF margin-74.6%
EBITDA margin3.4%

Returns

ROE—
ROA4.8%
ROIC (approx.)—
Asset turnover0.57x

Leverage & solvency

Liabilities / assets107.4%
Debt / equity—
Current ratio4.24x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-8.88x
Accruals ratio47.0%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$30.91M$22.60M
R&D expense$85.47M$94.53M
SG&A expense$27.55M$28.36M
Operating income-$86.39M-$102.68M
Pretax income—-$86.62M
Income tax$0$0
Net income-$74.28M-$86.62M
EBITDA-$83.06M-$99.56M
EPS (basic)-1.18-1.58
EPS (diluted)-1.18-1.58
Weighted avg. shares (diluted)62.98M54.90M
Balance sheet
Cash & equivalents$80.88M$57.16M
Current assets$163.24M$249.60M
PP&E, net$1.92M$9.96M
Total assets$198.10M$283.98M
Current liabilities$59.74M$66.99M
Total liabilities$306.60M$329.51M
Shareholders' equity-$108.50M-$45.53M
Shares outstanding56.66M55.59M
Cash flow statement
Operating cash flow-$86.10M-$100.41M
Capital expenditure$50,000$906,000
Free cash flow-$86.15M-$101.31M
Investing cash flow$112.04M-$29.90M
Financing cash flow$1.02M$105.43M
Depreciation & amortization$3.33M$3.12M
Stock-based compensation$10.40M$11.89M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.